This trial is evaluating whether SBRT will improve 1 primary outcome and 3 secondary outcomes in patients with Stereotactic Body Radiation Therapy. Measurement will happen over the course of Up to 4 weeks.
This trial requires 48 total participants across 1 different treatment group
This trial involves a single treatment. SBRT is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Sbt-related diseases are frequent in clinical practice. The reported data reveal that liver tumors occur in a significant percentage of Sbt-treated patients, and therefore deserve recognition for this drug. Sbt could play an active role in the management of these patients." - Anonymous Online Contributor
"Liver neoplasias frequently originate in the cirrhotic liver and are sometimes a sign of underlying hepatitis B/C. The role of other possible factors, such as chronic pancreatitis, drug-induced liver injury, or certain dietary (hepatic) factors, is less firmly established. The liver of patients who develop liver tumors may be defective because of damage from alcohol, viral infection, or other physical factors. Liver cancer in the West is primarily caused by infection with hepatitis B. A hepatitis C co-infection is associated with the development of liver cancer." - Anonymous Online Contributor
"Liver neoplasms will never be cured. However, they can be greatly reduced in certain cases, and this can be achieved through many different modalities, such as radical surgery, radiofrequency ablation, radiofrequency ablation combined with embolization and interferon." - Anonymous Online Contributor
"Liver neoplasms are benign, non-cancerous masses that are found in 5% of patients who suffer from liver disorders. Usually, liver tumors have an indolent course, and there is no evidence of malignancy, including the presence of cancer cells, in benign lesions. Nevertheless, patients should be encouraged to take periodic liver checkups and to undertake the most appropriate diagnostic methods. The most common benign tumors are lipoma, hamartoma, hemangiomas, focal nodular hyperplasia, and hepatocellular adenoma. They pose no major problems or complications and there is no need to undergo urgent intervention." - Anonymous Online Contributor
"Generally, benign liver tumors are treated via conservative or focal therapies, while the treatment of malignant liver tumors is often palliative due to the advanced stage of disease. Radical surgery, radiation, and chemoembolization are common treatment methods, while some patients may benefit from hepatocellular transplantation." - Anonymous Online Contributor
"In patients with unexplained encephalopathy, a high incidence of liver neoplasms (6.4%) was found. For patients who presented with nonspecific symptoms, liver lesions and a positive laboratory workup were more frequent. More patients with liver lesions required liver transplantation. Liver biopsy was more frequent in the presence of systemic and nutritional complications and liver enzyme values and was predictive of liver lesions." - Anonymous Online Contributor
"The incidence and mortality rates of liver cancer are rising in women. The higher incidence of liver cancer in U.S. women must be carefully investigated to evaluate risk factors that might be associated with increased risk for liver cancer." - Anonymous Online Contributor
"Liver neoplasms have the ability to spread and therefore the metastatic behavior of these tumors depends on the type of growth form, presence or absence of capsule, and size of the tumor. The metastatic behavior was determined by the following parameters: the degree of differentiation, the presence or absence of neoplastic capsule, and the presence of vascular invasion." - Anonymous Online Contributor
"sbrt may be an effective immunotherapy for HCC. It is very promising that the combination strategy of Sbrt with PD-1 inhibition represents a promising anti-cancer therapeutic immunotheraputic treatment in HCC patients." - Anonymous Online Contributor
"Lifestyle risk factors seem to decrease the risk of developing liver neoplasms, but they cannot compensate entirely for genetic and familial risk factors. Patients who are asymptomatic have higher risks of liver neoplasms developing." - Anonymous Online Contributor
"The current treatments were only palliative and do not provide durable survival or quality of life for patients. New treatments to combat liver carcinogenesis are urgently needed, and a combination therapy with chemotherapy and antiangiogenic drugs represents a new alternative for treatment. TACE is a novel therapy option that has shown good and predictable results on the short term in a short number of cases. There is also evidence suggesting that TACE may have less severe effects in liver carcinogenesis, which could be more clinically relevant in patients with comorbidities. Longer studies, with larger sample sizes, are necessary to assess the clinical effectiveness of TACE as a novel anti-neoplasm therapy in patients with liver malignancies." - Anonymous Online Contributor
"Recent advances in chemotherapy and surgery have greatly improved the survival of patients with [liver cancer](https://www.withpower.com/clinical-trials/liver-cancer), and liver disease has received far less attention than that of other types of cancer. We need to acknowledge these realities so that better treatment plans may be devised for all patients with liver cancer, not just those at the forefront of current medical science." - Anonymous Online Contributor